[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387394":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":24,"studyPopulation":25,"armGroups":26,"interventions":57,"overallOfficials":67,"centralContacts":72,"locations":82,"responsibleParty":99,"collaborators":20,"id":101,"slug":20,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":20,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":20,"enrollmentInfo":109,"targetDuration":20,"studyType":112,"phases":20,"briefSummary":113,"conditions":114,"keywords":20,"overallStatus":85,"whyStopped":20,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"PFS","Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)","5 years",[14,17],{"measure":15,"description":16,"timeFrame":12},"OS","Defined as the time from the start of treatment to the death of the subject due to any cause.",{"measure":18,"description":19,"timeFrame":12},"ORR","Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects.",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"COHORT","RETROSPECTIVE","inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history","Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China",[27,32,36,41,45,49,53],{"label":28,"type":20,"description":29,"interventionNames":30},"Cohort 1 Uncommon EGFR exon 19del","patients with uncommon EGFR exon 19del",[31],"Drug: Third-generation EGFR-TKI",{"label":33,"type":20,"description":34,"interventionNames":35},"Cohort 2 EGFR exon 19delins","patients with EGFR exon 19delins",[31],{"label":37,"type":20,"description":38,"interventionNames":39},"Cohort 3 EGFR exon 18del","patients with EGFR exon 18del",[40],"Drug: EGFR-TKI",{"label":42,"type":20,"description":43,"interventionNames":44},"Cohort 4 Common Uncommon Point Mutations","patients with common uncommon point mutations",[40],{"label":46,"type":20,"description":47,"interventionNames":48},"Cohort 5 Rare Uncommon Point Mutations","patients with rare uncommon point mutations",[40],{"label":50,"type":20,"description":51,"interventionNames":52},"Cohort 6 Compound Mutations Uncommon With Uncommon","patients with compound mutations uncommon with uncommon",[40],{"label":54,"type":20,"description":55,"interventionNames":56},"Cohort 7 Compound Mutations Uncommon With Common","patients with compound mutations uncommon with common",[40],[58,63],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":20},"DRUG","Third-generation EGFR-TKI","Third-generation EGFR-TKI including Osimertinib\u002FFurmonertinib\u002FAlmonertinib, etc.",[28,33],{"type":59,"name":64,"description":65,"armGroupLabels":66,"otherNames":20},"EGFR-TKI","All EGFR-TKI",[37,42,46,50,54],[68],{"name":69,"affiliation":70,"role":71},"Yongchang Zhang, MD","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[73,78],{"name":69,"role":74,"phone":75,"phoneExt":76,"email":77},"CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":79,"role":74,"phone":80,"phoneExt":75,"email":81},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[83],{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":96,"contacts":97},"Yongchang Zhang","RECRUITING","Changsha","Hunan","410013","China","CN",{"type":92,"coordinates":93},"Point",[94,95],112.97087,28.19874,{"lat":95,"lon":94},[98],{"name":69,"role":74,"phone":75,"phoneExt":75,"email":77},{"type":71,"investigatorFullName":84,"investigatorTitle":100,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"professor","100387394",false,"NCT04324164","Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC","Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China","Inclusion Criteria:\n\n* 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n\n  * Uncommon EGFR Mutant Advanced NSCLC\n\nExclusion Criteria:\n\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","ALL","18 Years",{"count":110,"type":111},800,"ESTIMATED","OBSERVATIONAL","This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China",[115],"Non-small Cell Lung Cancer","2025-01-23",{"date":118,"type":119},"2025-01-27","ACTUAL",{"date":121,"type":119},"2020-03-24",{"date":123,"type":111},"2027-12-24",{"name":5,"class":6},1]